PRESS RELEASE published on 04/22/2025 at 12:12, 1 year 4 months ago Inside Information / Other news releases Arkema discloses trading in own shares with buyback transactions from 14 to 17 April 2025 in compliance with regulations. Visit Arkema's website for more details Share Buyback Trading Compliance Regulations ARKEMA
BRIEF published on 04/15/2025 at 14:10, 1 year 4 months ago Arkema : Transactions sur Actions Propres Déclarées Actions Propres Transactions Financières Réglementation UE Achat D'actions ARKEMA
BRIEF published on 04/15/2025 at 14:10, 1 year 4 months ago Arkema: Transactions in Own Shares Reported Financial Transactions Own Shares EU Regulations Purchase Of Shares ARKEMA
PRESS RELEASE published on 04/15/2025 at 14:05, 1 year 4 months ago Informations privilégiées / Autres communiqués Arkema déclare les transactions sur actions propres du 07 au 11 avril 2025, se conformant à la réglementation. Détails sur le site du groupe Actions Propres Transactions Réglementation Site Internet ARKEMA
BRIEF published on 04/11/2025 at 12:17, 1 year 5 months ago Franchissement de seuil par BlackRock dans le capital d'ARKEMA Capital Franchissement De Seuil Actions BlackRock ARKEMA
BRIEF published on 04/11/2025 at 12:17, 1 year 5 months ago BlackRock crosses the threshold in ARKEMA's capital Capital Actions BlackRock Threshold Crossing ARKEMA
PRESS RELEASE published on 04/11/2025 at 12:12, 1 year 5 months ago Franchissement de seuil Déclaration de franchissement de seuil par BlackRock Inc. pour ARKEMA, passant à 4,99% du capital et 3,99% des droits de vote le 9 avril 2025 Déclaration Franchissement De Seuil BlackRock Inc. ARKEMA 5%
BRIEF published on 04/07/2025 at 12:54, 1 year 5 months ago Franchissement de seuil par BlackRock dans ARKEMA Franchissement De Seuil BlackRock Marché Boursier Gestion D'actifs ARKEMA
BRIEF published on 04/07/2025 at 12:54, 1 year 5 months ago BlackRock crosses the threshold in ARKEMA Asset Management Stock Market BlackRock Threshold Crossing ARKEMA
PRESS RELEASE published on 04/07/2025 at 12:49, 1 year 5 months ago Franchissement de seuil Déclaration de franchissement de seuil par BlackRock Inc. pour le compte de clients et fonds gérés, détenant 4,998% du capital et 3,996% des droits de vote d'Arkema Capital Déclaration Franchissement De Seuil BlackRock Inc. ARKEMA
Published on 09/11/2026 at 04:00, 8 hours 30 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 14 hours 5 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 21 hours 10 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 30 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 11:43, 46 minutes ago Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 54 minutes ago EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 59 minutes ago Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 2 hours 14 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 07:00, 5 hours 30 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 30 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 30 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
